Skip to main content

Posts

Muthoot Finance Q1FY22 Business Updates | Q1FY22 Results | Muthoot finance share

  MUTHOOT FINANCE Q1FY22 BUSINESS UPDATES KEY BUSINESS UPDATES  - CONSOLIDATED PERFORMANCE  -   KEY  POINTS  -  *  Break up of Muthoot Finance Assets in Muthoot group  - 90% * Break up of Subsidiaries in Muthoot group - 10% ----------------------------------- KEY POINTS -  *  Break up of Muthoot Finance Assets in Muthoot group - 99% *  Break up of Subsidiaries in Muthoot group - 1% -------------------------------- KEY POINTS -  * Interest Income grow by 15% (y-o-y) * Total Income grow by 14% (y-o-y) * PBT is grown by 14% (y-o-y) * PAT is grown by 14% (y-o-y) ------------------------------ KEY POINTS -  * Total loan book grow by 26.7% * Total Assets grow by 17.3% * Borrowing is grown by 13.2% * Borrowing from debt securities is grown by 47% ------------------------- MUTHOOT FINANCE STANDALONE PERFORMANCE -  KEY POINTS -  * Total Income is grown by 14% * Total Expenses is grown by 12% * PBT is grown by 16% * PAT is grown by 16% ---------------------------- KEY POINTS -  * Total Go
Recent posts

Alkem laboratories share Q1FY22 Earning Call Highlights | Key Highlights | Alkem lab share price

Alkem Labs Q1FY22 Earning Call Highlights ANALYST -  MR. TUSHAR MANUDHANE – MOTILAL OSWAL FINANCIAL SECURITIES LIMITED MANAGEMENT -  MR. SANDEEP SINGH –MANAGING DIRECTOR - ALKEM LABORATORIES MR. RAJESH DUBEY – CHIEF FINANCIAL OFFICER - ALKEM LABORATORIES MR. AMIT GHARE – PRESIDENT (INTERNATIONAL BUSINESS) - ALKEM LABORATORIES MR. YOGESH KAUSHAL - PRESIDENT CHRONIC DIVISION - ALKEM LABORATORIES MR. GAGAN BORANA –INVESTOR RELATIONS - ALKEM LABORATORIES Key Q1FY22 Business Updates -  * Revenue is growing  by 37.1% (y-o-y) * EBITDA margins are at 21.7% (y-o-y) * PAT is growing by 11% (y-o-y) * Indian business is growing by 65.3% (y-o-y) * US business is degrowth by 9.3% (y-o-y) * Other Internation business is growing by 56.4% (y-o-y) * During the quarter, we filled 2 ANDA with US FDA and received 5 approvals Some Important Question-Answer  -  Q1 - Just on the sales growth outlook especially for India business given that it is a very high growth how do you see the rest of the year pannin

Ipca labs share Q1FY22 Key Earning Call Highlight | Ipca labs share | Ipca labs news

     IPCA LABS Key Q1FY21 Earning Call Highligh t -  ANALYST : MR. NITIN AGARWAL – DAM CAPITAL ADVISORS LIMITED  MANAGEMENT :  MR. A.K JAIN – JOINT MANAGING DIRECTOR – IPCA LABORATORIES LIMITED MR. HARISH KAMATH – CORPORATE COUNSEL & COMPANY SECRETARY – IPCA LABORATORIES LIMITED Some Q1FY22 Business Update s -  *  The domestic formulation business delivered 25% growth over previous year and excluding 54 Crores of domestic hydroxychloroquine, institutional business which we have done in last year Q1, if we exclude that then domestic formulation business has grown by almost around 41% in Q1 on a lower base *  Our Pain segment has given almost around 36% growth which contributes almost around 49% of our businesses * Cardiovascular and Antidiabetic has grown by almost around 14%, which contribute almost around 18% of the business, Antibacterial has done really very well. The business from 18 Crores has gone to almost around 50 Crores. It contributes around 8% of the business and overal

Suven Pharmaceutical Q4&FY21 Business Updates | suven pharma news | q4 results 2021

                     Suven Pharmaceutical ltd Q4&FY21 Business Updates   Company Overview -  • Suven is an integrated Contract Development and Manufacturing Operations company • Integrated CDMO company with strong capabilities right from process research & development to late stage clinical and commercial manufacturing. • Suven provides services to leading Global Life Science and Fine Chemical majors including Custom Synthesis, Process R&D, Scale Up and Contract Manufacturing of intermediates, APIs and formulations. Financial Results -  Key Q4 Financial Highlights - • Revenue - 2624 million ( 38%) ( y-o-y ) • EBITDA - 969 million ( 18%) ( y-o-y ) • EBITDA Margin - 37% • PAT - 831 million ( 12%) ( y-o-y ) • PAT Margin - 31.37 % Key FY21 Financial Highlights -  • Revenue - 10,239   million ( 20%) ( y-o-y ) • EBITDA -  4547 million (13.75%)  ( y-o-y ) • EBITDA Margin - 44.4% • PAT - 3623 million ( 14.3%)  ( y-o-y ) • PAT Margin - 35.4% • EBIT to Income - 41.32% • EBITDA to

Au small finance bank share Q4&FY21 Business Updates | q4 result | au small finance bank news

                 AU SMALL FINANCE BANK   Q4&FY21 BUSINESS UPDATES   Key Q4FY21 Highlight -  Q4FY21 Quarterly Result -  Key FY21 Financial Highlights -  FY21 Annual Result -  Other Income Statement -  Balance Sheet -  Assets & Liabilities Breakup -  Key FY21 Operational Highlights -  ➢ Strong rebound in disbursement in H2 (Vehicle, SBL and Housing)  ➢ 77% of total FY21 disbursement in H2 (47% YoY growth) ➢ Deposits continue to scale driven by increasing brand awareness, branch expansion and improved digital offering ➢ Improved CASA ratio from 14% to 23% ➢ Overall Cost of Funds reduced by 86 bps to 6.83% from 7.69% in FY20 ➢ GNPA of ₹ 1,503 Cr (4.3%), of which ➢ >90DPD portfolio - ₹ 962 Cr (2.7%)  ➢ <90 DPD portfolio - ₹ 541 Cr (1.5%) ➢ Collection efficiency was >100% in each month of Q4FY21 ➢ PAT (ex-Aavas) grew YoY despite accelerated provisions in FY21 ➢ Deposit are at 35,979 crore ( Growth of 38%)(y-o-y) Share Holdings Pattern - 

IOLCP Share Q4&FY21 Business Updates | Q4 Results | Stock Market

       I OLCP Q4&FY21 Business Updates   Company Overview -  • Incorporated in 1986, IOLCP is one of the leading Pharmaceuticals company and is a significant player in the field of specialty chemicals with world class facilities • Largest producer of Ibuprofen and the only company worldwide being backward integrated with ~35% Global share • Largest producer of Ethyl Acetate at Single Location in India • 2nd Largest producer of Iso Butyl Benzene (IBB) with ~30% Global share • Over 20 products are commercialised with 8 products in pipeline • Debt free company, No debt raised since 2017 • Customer base across 80 countries. Key Financial Summary -  P&L Statement -  Balance sheet  -  Pharmaceuticals Product wise Segmentation -  Chemicals Product wise Segmentation -  Key Financial Numbers -  1. Imports (in crore) - 613 crore 2. Export (in crore) - 1354 crore 3. Debt/equity  - 0 4. Pharma EBITDA Margin - 39% 5. Chemical EBITDA Margin - 12% * Dr. Sanjay Chaturvedi is appoin

Alkem lab share Q4 results 2021 | Business Updates | best stocks to buy today

                Alkem laboratories ltd Q4&FY21 Business Updates Overview  - Alkem laboratories is established in 1973. Alkem Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra, India that manufactures and sells pharmaceutical generics, formulations and nutraceuticals in India and globally . Q4-FY21 Financial Highlights -  * Revenue from Operations -  * Revenue from India -  * Revenue from Outside -  * EBITDA And EBITDA Margins -  * Profit After Tax -    FY21:Key Financial Highlights   Indian Business -  • India sales contributed 68.1% to total sales in Q4FY21 • Company witnessed good recovery in the second half of the financial year compared to YoY decline in the first half • Company’s Trade Generic business delivered a robust growth during the quarter and the financial year • In Q4FY21, the Company’s secondary sales grew by 9.8% YoY compared to IPM growth of 8.5% YoY (Source: IQVIA data) • During the quarter, the Com